In 2012 Lindsey completed her studies in Biomedical sciences at the Radboud University in Nijmegen, and graduated with majors in Occupational and Environmental Health and in Toxicology. In august 2012 she started her PhD at the Radboud university medical center, in which she studied the molecular mechanisms underlying (un)wanted transporter mediated drug-drug interactions and assessed the pharmacokinetics and drug-related adverse events of TB drugs as part of multiple drug therapy in TB patients. For the pharmacokinetic studies she spent considerable time at Universitas Padjadjaran and Hasan Sadikin hospital in Bandung, Indonesia, an important partner in tuberculosis research for the Radboudumc. During her PhD Lindsey also completed the training required for the register of professional toxicologists by the Netherlands Society of Toxicology (NVT). After finishing her PhD, in January 2017, Lindsey is continuing her work as a postdoctoral researcher, studying potential new and safe drug regimens against tuberculous meningitis. Furthermore starting from March 2017, she is working as project manager on PanACEA-II, focusing on HIGHRIF1, trial and consortium coordination, drug management, pharmacology, and providing scientific support.
Dr. Lindsey te Brake
